Thus, confirming the ability of our specific EVs to enter the CNS via the nasal delivery route and target oligodendrocytes is a significant step towards determining the utility of IFNγ-DC-EVs as a therapeutic for demyelinating disorders. The gene discussed is IFNG; the disease is demyelinating disease.